SCHEMBL33526836

SCHEMBL33526836

CC(C)(Cn1nc(C(F)(F)F)cc1-c1ccnc(C(C)(C)O)c1)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 7/20 0.41
AAK1 Q2M2I8 5/20 0.37
HDAC3 O15379 2/20 0.37
HDAC4 P56524 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC7 Q8WUI4 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC10 Q969S8 2/20 0.37
HDAC11 Q96DB2 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
HDAC9 Q9UKV0 2/20 0.37
HDAC5 Q9UQL6 2/20 0.37
NCOR2 Q9Y618 2/20 0.37
NR3C2 P08235 3/20 0.36
PTGS2 P35354 1/20 0.36
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31752941 0.86 HDAC3 (0.39) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL31753106 0.84 HDAC3 (0.36) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL33526401 0.82 HDAC3 (0.39) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL34466824 0.82 HDAC3 (0.41) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL31753203 0.81 HDAC3 (0.39) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL33526240 0.80 HDAC3 (0.36) AAK1HDAC3HDAC4HDAC1HDAC7
SCHEMBL33526391 0.80 HDAC3 (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL33527226 0.80 HDAC3 (0.33) AAK1HDAC3HDAC4HDAC1HDAC7
Hydrochloric Acid SCHEMBL33527139 0.78 TGFBR1 (0.42) TGFBR1AAK1HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL31752744 0.78 TGFBR1 (0.42) TGFBR1AAK1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-23 US disclosed
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GPR119 TGFBR1 605/4885AAK1 2749/4885HDAC3 316/4885
US-20260108546-A1 GIP RECEPTOR AGONIST COMPOUNDS GIPR, GLP1R, GCGR TGFBR1 406/4885AAK1 3435/4885HDAC3 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.